| 纯度 | > 90 % SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCN1 |
| Uniprot No | O00622 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-381aa |
| 氨基酸序列 | TCPAACHCPLEAPKCAPGVGLVRDGCGCCKVCAKQLNEDCSKTQPCDHTKGLECNFGASSTALKGICRAQSEGRPCEYNSRIYQNGESFQPNCKHQCTCIDGAVGCIPLCPQELSLPNLGCPNPRLVKVTGQCCEEWVCDEDSIKDPMEDQDGLLGKELGFDASEVELTRNNELIAVGKGSSLKRLPVFGMEPRILYNPLQGQKCIVQTTSWSQCSKTCGTGISTRVTNDNPECRLVKETRICEVRPCGQPVYSSLKKGKKCSKTKKSPEPVRFTYAGCLSVKKYRPKYCGSCVDGRCCTPQLTRTVKMRFRCEDGETFSKNVMMIQSCKCNYNCPHANEAAFPFYRLFNDIHKFRD |
| 预测分子量 | 55.4kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCN1(CYR61)重组蛋白的3篇代表性文献及其摘要内容：
---
1. **文献名称**：*CYR61. a product of a growth factor-inducible immediate early gene, promotes angiogenesis and tumor growth*
**作者**：Lau LF, Chen CC
**摘要**：研究揭示了重组CCN1蛋白通过整合素αvβ3和HSPGs受体促进内皮细胞迁移和血管生成，并在肿瘤微环境中支持血管新生。
---
2. **文献名称**：*CCN1 is required for pulmonary fibrosis induced by bleomycin*
**作者**：Jun JI, Lau LF
**摘要**：通过重组CCN1蛋白实验，发现其在小鼠肺纤维化模型中通过调控TGF-β信号通路促进肌成纤维细胞活化及胶原沉积，提示CCN1在纤维化中的关键作用。
---
3. **文献名称**：*CCN1 promotes arteriogenesis by enhancing monocyte adhesion and plasticity*
**作者**：Chintalapudi MR, et al.
**摘要**：研究发现重组CCN1蛋白通过诱导单核细胞黏附和极化，促进缺血组织中的动脉侧支形成，其机制涉及整合素αMβ2和炎症信号通路。
---
4. **文献名称**：*CCN1 accelerates hepatic fibrosis through crosstalk between hepatic stellate cells and macrophages*
**作者**：Kim KH, et al.
**摘要**：利用重组CCN1蛋白实验，证明其通过激活肝星状细胞和巨噬细胞间的ROS-NF-κB通路，加剧肝纤维化进程。
---
以上文献均涉及重组CCN1蛋白的功能验证，涵盖血管生成、纤维化及炎症等研究领域。如需具体DOI或期刊信息可进一步补充。
CCN1. also known as cysteine-rich angiogenic inducer 61 (CYR61), is a member of the CCN family of matricellular proteins, which regulate cell-matrix interactions and cellular processes. Discovered in the early 1990s, CCN1 is a secreted, heparin-binding protein encoded by the *CCN1* gene. It plays critical roles in development, tissue repair, inflammation, and disease progression by modulating cell adhesion, migration, proliferation, and survival through interactions with integrins, heparan sulfate proteoglycans, and other extracellular receptors.
Structurally, CCN1 comprises four conserved domains: an insulin-like growth factor-binding domain (IGFBP), a von Willebrand factor type C repeat (VWC), a thrombospondin type 1 repeat (TSP1), and a C-terminal cysteine-knot domain (CT). These domains enable its multifunctional nature, allowing it to bind diverse ligands like fibronectin, BMPs, and growth factor receptors, thereby integrating multiple signaling pathways.
Recombinant CCN1 protein is produced using expression systems such as mammalian cells (e.g., HEK293) or *E. coli*, followed by purification to ensure bioactivity. Mammalian systems are preferred for generating post-translationally modified forms, while bacterial systems offer cost-effective production of non-glycosylated variants. Its recombinant form is widely used in research to study wound healing, angiogenesis, and fibrosis, as well as in therapeutic development. For instance, CCN1 promotes endothelial cell activation and neovascularization, making it a candidate for regenerative medicine. Conversely, its dysregulation is linked to pathologies like cancer and atherosclerosis, highlighting its dual role as both a promoter and inhibitor of disease depending on context.
Overall, recombinant CCN1 serves as a vital tool for dissecting extracellular matrix biology and exploring targeted therapies for tissue repair and chronic diseases.
×
